WHO ICTRP trial
Orteronel (TAK-700 study) in granulosa cell ovarian tumors.
EUCTR2013-003128-35-ES · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2013-003128-35-ES |
|---|---|
| Public title | Orteronel (TAK-700 study) in granulosa cell ovarian tumors. |
| Scientific title | Open label phase II clinical trial of Orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors. The Greko II study. - GREKO II |
| Primary sponsor | Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI) |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Spain;Spain;Spain |
| Conditions | Metastatic or advanced non-resectable granulosa cell ovarian tumors MedDRA version: 17.0 Level: PT Classification code 10057376 Term: Ovarian granulosa-theca cell tumour System Organ Class: 10029104 - Neoplasms benign, malignant and… |
| Interventions | Product Name: Orteronel Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ORTERONEL Current Sponsor code: TAK-700 Other descriptive name: ORTERONEL Concentration unit: mg milligram(s) Concentration type: equal Concentration… |
| Registration date | Mar 13, 2014 |
| Secondary IDs | GETHI-2013-01;GETHI-2013-01;GETHI-2013-01 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: